Daré Bioscience, Inc. (DARE) 股票分析

公司概述

Daré Bioscience, Inc. is a specialized biotechnology entity focused on developing and commercializing therapies within the United States, targeting critical areas such as contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health. The company's product portfolio currently includes XACIATO, a lincosamide antibacterial gel designed specifically for the treatment of bacterial vaginosis, alongside ongoing development efforts in other therapeutic domains. Operating within the broader healthcare sector and specifically the biotechnology industry, the company leverages scientific innovation to address unmet medical needs in women's health. As of the latest reporting period, Daré Bioscience, Inc. maintains a market capitalization of $26.94 million, generates annual revenue of $1.03 million, and employs a workforce of 21 individuals. These financial dimensions indicate that the company operates at a small-cap scale, characteristic of early-stage biotechnology firms where revenue generation is often limited while significant capital is allocated to research and development activities rather than immediate profit maximization.

财务健康

The company reported a trailing twelve-month revenue of $1.03 million, yet this figure contrasts sharply with a net income loss of $13,399,274, revealing a cost structure where operating expenses substantially exceed top-line earnings. This substantial gap between revenue and net income underscores the high burn rate typical of biotechnology companies in the development phase, where costs for clinical trials and personnel far outweigh current sales. The company recorded an EBITDA of $-11,917,848 and a free cash flow of $-4,802,669, indicating that its current financial flexibility relies heavily on cash reserves rather than operational cash generation. Despite these negative cash flows, Daré Bioscience, Inc. holds a cash balance of $24.71 million, which provides a buffer against its debt obligations of $2.66 million, though the debt-to-equity ratio stands at a high 93.44. The balance sheet reflects a leveraged position given the elevated debt relative to equity, yet the significant cash hoard suggests management is prioritizing liquidity preservation over aggressive debt repayment. Profitability metrics further highlight this developmental stage, with a gross margin of 71.3% indicating efficient production, but an operating margin of -143.7% and a profit margin of 0.0% demonstrating that the company is not yet profitable on an operational or net basis. Return on equity is unavailable due to lack of earnings, while return on assets stands at -31.0%, revealing that the company's asset base is currently generating negative returns. Finally, the current ratio is 1.14, which indicates that the company possesses just enough current assets to cover its short-term liabilities, suggesting a tight but manageable short-term liquidity position.

估值评估

Daré Bioscience, Inc. presents a unique valuation profile for a pre-revenue or low-revenue biotechnology firm, exhibiting a trailing P/E ratio of N/A because it has not generated positive earnings over the trailing twelve months. However, the forward P/E is listed at 2.03, a metric that implies market expectations for future earnings normalization or a specific accounting treatment for anticipated profitability, though the divergence from the trailing metric highlights the current lack of historical earnings data. The price-to-book ratio is 9.44, indicating that the market values the company at a significant premium over its net asset book value, likely reflecting the intangible value of its intellectual property and potential pipeline assets. Additionally, the price-to-sales ratio is 26.15, which is extremely high relative to its $1.03 million revenue, suggesting investors are pricing in substantial future growth potential or successful clinical outcomes rather than current cash flows. The EV/EBITDA stands at -0.41, further confirming that traditional enterprise value multiples are not applicable in the conventional sense due to negative earnings before interest, taxes, depreciation, and amortization. In terms of trading range, the stock has a 52-week high of $9.19 and a 52-week low of $1.27, meaning the current market price sits within this wide volatility band, reflecting the high-risk nature of small-cap biotech stocks. The beta value is 0.90, which indicates that the stock's price volatility moves in line with the broader market, neither exhibiting extreme sensitivity nor insulating itself from general market fluctuations.

Growth & Income

The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet achieved the scale or profitability required to calculate meaningful historical growth rates. Consequently, earnings cannot be compared to revenue growth in a traditional sense, as the negative earnings negate the concept of growth velocity relative to sales in the short term. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available cash and generated income are retained and reinvested directly into research, development, and clinical trials rather than distributed to shareholders. This reinvestment strategy is standard for biotechnology firms in the development stage, where capital deployment into pipeline assets is prioritized over providing immediate income to investors. The overall growth and income profile of Daré Bioscience, Inc. is defined by a complete reliance on capital appreciation potential driven by future product approvals and clinical data rather than current dividend yields or established revenue growth trajectories.